RxDoctor Payments Data

Mark Handelman, MD

Internal Medicine · Las Vegas, NVNPI 1194798132

Payments from drug & device makers

$705in general payments, 2019–2025

Across 21 payments — averaging $33.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$436
  • Pfizer$55
  • Sanofi-aventis U.S. LLC$47
  • Novo Nordisk$44
  • Astellas Pharma US Inc$41
  • Amarin Pharma, Inc.$23
  • plus $58 from 3 others

What the payments were for

  • Food & beverage$33648%
  • Education$36952%

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$705 in reported general payments places this provider in the 65th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$213,862
Medicare patients
343
Services billed
2,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$98,272
MounjaroTirzepatide72$91,944
JardianceEmpagliflozin48$79,297
Dupixent SyringeDupilumab13$57,382
EliquisApixaban50$56,930
FarxigaDapagliflozin Propanediol35$42,315
TrulicityDulaglutide26$42,259
ProliaDenosumab23$39,358
XareltoRivaroxaban20$25,351
MyrbetriqMirabegron23$25,072
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$18,701
RybelsusSemaglutide16$17,825
RexultiBrexpiprazole12$17,687
KerendiaFinerenone14$11,168
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt13$7,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$44$116,09778 claims
PfizerEliquis, Paxlovid$55$58,359104 claims
AmgenProlia$436$39,35823 claims
Astellas Pharma US IncMyrbetriq$41$25,07223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →